Streetbeat News

Analyst Ratings

GEL

RBC Capital analyst Elvira Scotto maintains an Outperform rating on Genesis Energy (NYSE:GEL) and raises the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:13 pm

EVCM

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on EverCommerce (NASDAQ:EVCM) but lowers the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:11 pm

BMRN

RBC Capital analyst Luca Issi has reiterated a 'Sector Perform' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:09 pm

BNBUSD

BTCUSD

CryptoQuant's J. A. Maartunn warns of potential crypto market turbulence, citing a metric that currently stands at $13.8 billion, which could be a precursor to market turbulence. Historically, whenever this metric crossed the $12.2 billion mark, it led to at least a 20% drop in Bitcoin value. CryptoSlate's James Van Straten also noted a significant uptick in the open interest in Bitcoin, which may indicate a shift in investor sentiment or the adoption of defensive strategies amidst market uncertainty.

Portfolio Pulse from Murtuza Merchant

November 07, 2023 | 6:08 pm

COLD

RBC Capital analyst Michael Carroll has maintained an 'Outperform' rating on Americold Realty Trust (NYSE:COLD) but lowered the price target from $38 to $34.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:08 pm

ACHC

RBC Capital analyst Ben Hendrix has maintained an 'Outperform' rating on Acadia Healthcare Co (NASDAQ:ACHC) but lowered the price target from $99 to $94.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:06 pm

IMO

RBC Capital analyst Greg Pardy has maintained a 'Sector Perform' rating on Imperial Oil and raised the price target from C$80 to C$85.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:00 pm

PGR

17 analysts have given their ratings on Progressive (NYSE:PGR) over the last quarter. The average price target is $145.71, which is lower than the current price of $157.61. The average price target has increased by 11.18% over the past month.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 6:00 pm

PAYX

In the last quarter, Paychex (NASDAQ:PAYX) received 9 analyst ratings, with 2 somewhat bullish, 5 indifferent, and 2 somewhat bearish. The company's average 12-month price target is $124.78, a 4.86% increase from the previous average of $119.00.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 6:00 pm

VRTX

Over the past 3 months, 10 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. The average price target is $383.1, implying an upside from the current price of $377.4. The current average has increased by 5.73% from the previous average price target of $362.33.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 6:00 pm